Placebo News and Research

RSS

Lithium aspartate fails to improve long COVID symptoms, but higher doses may hold promise

Lithium aspartate at 10-15 mg/d is ineffective for treating cognitive dysfunction and fatigue in long COVID, but higher doses may offer potential benefits based on a small follow-up study.

3 Oct 2024

Low-dose lithium fails in long COVID trial, but higher doses show potential

A small University at Buffalo clinical trial has found that at low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of long COVID; however, a supplemental dose-finding study found some evidence that higher doses may be effective.

3 Oct 2024

Dronabinol shows promise in reducing agitation in Alzheimer's patients

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana's main ingredient, THC, reduces agitation in patients with Alzheimer's by an average of 30%.

2 Oct 2024

Glutathione found to significantly reduce acetaldehyde levels and help relieve hangovers

Study demonstrates that glutathione (GSH) significantly reduces acetaldehyde levels, a key factor in hangovers, though subjective symptoms showed little difference between groups. Pharmacokinetic data indicate that GSH accelerates acetaldehyde clearance, providing potential relief from hangover symptoms.

29 Sep 2024

12-week coffee compound study shows promising results for weight and fat reduction in at-risk individuals

Cafestol may aid in reducing body weight and visceral fat, but its impact on insulin sensitivity and glucose tolerance remains limited, according to the study.

27 Sep 2024

Targeted drug therapy shows promise for ulcerative colitis remission

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.

26 Sep 2024

Concerns raised over safety and effectiveness of donanemab for Alzheimer’s treatment

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

25 Sep 2024

Older adults face higher CVD risk post-cancer treatment

Older adults treated for cancer face twice the risk of developing cardiovascular diseases compared to those without cancer. The highest risks are seen in patients with metastatic, hematologic, and lung cancers, especially after chemotherapy.

25 Sep 2024

New study challenges dopamine's role in placebo effects and pain relief

New findings argue against a direct causal role for dopamine during the experience of a treatment effect in the establishment of positive treatment expectations and placebo analgesia in healthy volunteers, according to a study published September 24th in the open-access journal PLOS Biology by Ulrike Bingel from University Hospital Essen, Germany, and colleagues.

24 Sep 2024

Music therapy improves sleep and comfort in preterm infants

Daily music interventions significantly improved comfort and sleep transitions in preterm infants without affecting physiological stability. This study highlights the potential of non-pharmacological music therapy in neonatal care.

24 Sep 2024

Brain connectivity changes after psilocybin treatment in body dysmorphic disorder patients

Body dysmorphic disorder (BDD) is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one's physical appearance.

24 Sep 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

Triptans better at relieving migraine pain than recently marketed and more expensive drugs

A meta-analysis reveals triptans as the most effective acute migraine treatments, highlighting the need for their inclusion in the WHO Essential Medicines List.

23 Sep 2024

Brain scans reveal link between SSRI use and cognitive function

Researchers have found that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. They measured brain function in patients before and after taking the SSRI escitalopram and correlated this to a drop in the level of one of the serotonin receptors in the brain and to cognitive improvements during treatment.

22 Sep 2024

Vitamin D during pregnancy boosts childhood bone health for years, study shows

Researchers examine the persistence of this improvement in bone mineral density from the MAVIDOS trial into later childhood years.

22 Sep 2024

Cranberry juice: A natural boost for women's skin health

A polyphenol-rich cranberry beverage was found to improve skin elasticity, reduce UV-induced erythema, and modulate the skin microbiome, with effects most pronounced in women aged 40 and older.

22 Sep 2024

Adaptive platform trial tests multiple treatments for traumatic brain injury

Traumatic brain injury (TBI) results in close to 70,000 deaths in the United States every year, and it is the cause of long-term physical, cognitive and mental disability in 5 million Americans. But despite three decades of work, treatments are sorely lacking.

19 Sep 2024

Placebo News and Research

Lithium aspartate fails to improve long COVID symptoms, but higher doses may hold promise

Low-dose lithium fails in long COVID trial, but higher doses show potential

Dronabinol shows promise in reducing agitation in Alzheimer's patients

Glutathione found to significantly reduce acetaldehyde levels and help relieve hangovers

12-week coffee compound study shows promising results for weight and fat reduction in at-risk individuals

Targeted drug therapy shows promise for ulcerative colitis remission

Concerns raised over safety and effectiveness of donanemab for Alzheimer’s treatment

Older adults face higher CVD risk post-cancer treatment

New study challenges dopamine's role in placebo effects and pain relief

Music therapy improves sleep and comfort in preterm infants

Brain connectivity changes after psilocybin treatment in body dysmorphic disorder patients

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

Triptans better at relieving migraine pain than recently marketed and more expensive drugs

Brain scans reveal link between SSRI use and cognitive function

Vitamin D during pregnancy boosts childhood bone health for years, study shows

Cranberry juice: A natural boost for women's skin health

Adaptive platform trial tests multiple treatments for traumatic brain injury

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

Triptans prove to be more effective for acute migraines than newer drugs

Blackcurrant supplements show promise in preventing bone density loss in post-menopausal women

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News